{"explains":[],"count":15,"quotes":[{"exchange":"NYQ","shortname":"Merck & Company, Inc.","quoteType":"EQUITY","symbol":"MRK","index":"quotes","score":29275.0,"typeDisp":"Equity","longname":"Merck & Co., Inc.","exchDisp":"NYSE","sector":"Healthcare","sectorDisp":"Healthcare","industry":"Drug Manufacturers—General","industryDisp":"Drug Manufacturers—General","dispSecIndFlag":true,"isYahooFinance":true},{"exchange":"GER","shortname":"MERCK KGAA O.N.","quoteType":"EQUITY","symbol":"MRK.DE","index":"quotes","score":20259.0,"typeDisp":"Equity","longname":"Merck KGaA","exchDisp":"XETRA","sector":"Healthcare","sectorDisp":"Healthcare","industry":"Drug Manufacturers—Specialty & Generic","industryDisp":"Drug Manufacturers—Specialty & Generic","isYahooFinance":true,"prevName":"MERCK Kommanditgesellschaft auf Aktien","nameChangeDate":"2023-10-21"},{"exchange":"GER","shortname":"MERCK CO.  DL-,01","quoteType":"EQUITY","symbol":"6MK.DE","index":"quotes","score":20056.0,"typeDisp":"Equity","longname":"Merck & Co., Inc.","exchDisp":"XETRA","sector":"Healthcare","sectorDisp":"Healthcare","industry":"Drug Manufacturers—General","industryDisp":"Drug Manufacturers—General","isYahooFinance":true},{"exchange":"PNK","shortname":"MERCK KGAA SPON ADR EACH REPR 0","quoteType":"EQUITY","symbol":"MKKGY","index":"quotes","score":20021.0,"typeDisp":"Equity","longname":"Merck KGaA","exchDisp":"OTC Markets","sector":"Healthcare","sectorDisp":"Healthcare","industry":"Drug Manufacturers—Specialty & Generic","industryDisp":"Drug Manufacturers—Specialty & Generic","isYahooFinance":true,"prevName":"MERCK Kommanditgesellschaft auf Aktien","nameChangeDate":"2023-10-21"},{"exchange":"JKT","shortname":"Merck Tbk","quoteType":"EQUITY","symbol":"MERK.JK","index":"quotes","score":20013.0,"typeDisp":"Equity","longname":"PT Merck Tbk","exchDisp":"Jakarta","sector":"Healthcare","sectorDisp":"Healthcare","industry":"Drug Manufacturers—Specialty & Generic","industryDisp":"Drug Manufacturers—Specialty & Generic","isYahooFinance":true},{"exchange":"DXE","shortname":"Merck KGaA","quoteType":"EQUITY","symbol":"MRKD.XD","index":"quotes","score":20006.0,"typeDisp":"Equity","exchDisp":"DXE","isYahooFinance":true},{"exchange":"FRA","shortname":"MERCK FINCK STIFT.BALA.UI","quoteType":"ETF","symbol":"UI2Y.F","index":"quotes","score":20004.0,"typeDisp":"ETF","longname":"Merck Finck Stiftungsfonds Balanced UI","exchDisp":"Frankfurt","isYahooFinance":true}],"news":[{"uuid":"83a24734-6f4c-3308-9b1e-ec19e59801e7","title":"KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","publisher":"Business Wire","link":"https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-143000732.html","providerPublishTime":1697985000,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/BoIU1oohIdp8tWFI19LkLg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6c283953a3ceb5c7cdeab8f6a5688676","width":480,"height":217,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/F8ysyGXk6XWj8PjHWVfwtQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6c283953a3ceb5c7cdeab8f6a5688676","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["MRK"]},{"uuid":"3c004fbd-bd28-38ce-84e4-0ca8249e8268","title":"Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)","publisher":"Business Wire","link":"https://finance.yahoo.com/news/merck-welireg-belzutifan-significantly-improved-124500107.html","providerPublishTime":1697892300,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/4rnQaAN4ykOFXfNqAzKaiA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/329870a63befc0780dcf7ad8d69be047","width":480,"height":217,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/uhvnV85KwZZhTWnV0lcrfA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/329870a63befc0780dcf7ad8d69be047","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["MRK"]},{"uuid":"7ef68392-0e3a-3d5d-b06b-18b7ccc71dbd","title":"Stock Market Today: Stock Market News And Analysis","publisher":"Investor's Business Daily","link":"https://finance.yahoo.com/m/7ef68392-0e3a-3d5d-b06b-18b7ccc71dbd/stock-market-today%3A-stock.html","providerPublishTime":1697846451,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/TQcagl7pYHbkxFjtqiLLlQ--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/28e88eac1c8027393a22cb7ae91a9299","width":945,"height":533,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/m.a9vz6xOcKz1GauLhh5xA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/28e88eac1c8027393a22cb7ae91a9299","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ENPH","MRK","SEDG","RF","RF-PB","RF-PE","AXP"]},{"uuid":"43d4228a-a052-3e80-b9c4-4a5a80cc7ff0","title":"Health Care Roundup: Market Talk","publisher":"The Wall Street Journal","link":"https://finance.yahoo.com/m/43d4228a-a052-3e80-b9c4-4a5a80cc7ff0/health-care-roundup%3A-market.html","providerPublishTime":1697835720,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/.qtp8vrhfIy9YF8YYl2AIw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/415bd7691b51b7ebfe7e0ae603ef79b1","width":1280,"height":640,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/MHnKuXxa5d1pMTnI8ZV2jQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/415bd7691b51b7ebfe7e0ae603ef79b1","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["RHHBF","RHHBY","RHHVF","MKGAF","MKKGY"]},{"uuid":"0e618d7e-29a4-3249-b345-34069d7e6495","title":"AT&T, Merck-Daiichi Sankyo, Klaviyo: Top Stocks","publisher":"Yahoo Finance Video","link":"https://finance.yahoo.com/video/t-merck-daiichi-sankyo-klaviyo-203022179.html","providerPublishTime":1697833822,"type":"VIDEO","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/SY7_zm.4mEPPpWDOc2lbcw--~B/aD0yNzc5O3c9NDk1MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2023-10/795bc6f0-6f87-11ee-acbb-d1f2ff71d2a9","width":4950,"height":2779,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/N8695L1U_vMH.lRHMom3rg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/os/creatr-uploaded-images/2023-10/795bc6f0-6f87-11ee-acbb-d1f2ff71d2a9","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["DSKYF","DSNKY","KVYO","MRK","T","T-PA"]},{"uuid":"03becd48-2bd2-3a3a-b284-677b47dca1d6","title":"Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs","publisher":"Zacks","link":"https://finance.yahoo.com/news/merck-mrk-inks-deal-daiichi-170200381.html","providerPublishTime":1697821320,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/Oiq_NB7PUJLxlOHbgJga3A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/cb27584804ea583a87d27499a6976ec2","width":635,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/xs3PyCV6UO68wTiEzNvHbA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/cb27584804ea583a87d27499a6976ec2","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["4568.T","MRK"]},{"uuid":"e1704759-6151-39c6-966f-47ff71c510c5","title":"Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer","publisher":"Business Wire","link":"https://finance.yahoo.com/news/merck-keytruda-pembrolizumab-plus-concurrent-140000413.html","providerPublishTime":1697810400,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/Fy_2KUYiTUc8IP9J550mlA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/26ceda81a056624fa55936d94ff83f59","width":480,"height":217,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/nwjRDfc688b2SCnp2VHreg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/26ceda81a056624fa55936d94ff83f59","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["MRK"]},{"uuid":"d8ad5d69-3ce8-3071-87a7-c1dde4fb2ae5","title":"Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer","publisher":"Business Wire","link":"https://finance.yahoo.com/news/merck-keytruda-pembrolizumab-plus-chemotherapy-120200361.html","providerPublishTime":1697803320,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/DZ3hoCJITSSU0.fai4SJlQ--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/83a37e16797916cfe066f00a3ec849ec","width":480,"height":217,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/eTHmpmNqWrKzS5x0fM.8MQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/83a37e16797916cfe066f00a3ec849ec","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["MRK"]}],"nav":[],"lists":[],"researchReports":[],"screenerFieldResults":[],"totalTime":114,"timeTakenForQuotes":457,"timeTakenForNews":600,"timeTakenForAlgowatchlist":400,"timeTakenForPredefinedScreener":400,"timeTakenForCrunchbase":0,"timeTakenForNav":400,"timeTakenForResearchReports":0,"timeTakenForScreenerField":0,"timeTakenForCulturalAssets":0}